Beraprost sodium delays the decline of glomerular filtration rate in people with diabetic nephropathy

The combination of conventional treatment and beraprost sodium therapy delays the decline of estimated glomerular filtration rate in people with diabetic nephropathy in the long term, research reveals.

From January 2015 to December 2021, a team of academics examined 50 adults who received a combination of conventional treatment and beraprost sodium (120 ug/day) therapy.

In addition, baseline information and clinical variable at each follow-up visit were collected from each participant.

The researchers found that serum albumin levels after treatment were improved in both groups, but the improvement was statistically significant only in the beraprost sodium therapy group.

The results state: “The estimated glomerular filtration rate worsened significantly in both groups (p = 0.009 and p = 0.001). However, the decline of eGFR was less in beraprost sodium therapy group than that in control group (− 9.8 vs. − 16.7 ml/min/1.73 m2, p = 0.037).

“In the subgroup analysis, 30 participants received three to 12 months treatment and the other 20 received more than 12 months treatment.”

They added: “During the three to 12 months treatment period, serum creatinine and estimated glomerular filtration rate in the control group were significantly worsened compared with those before treatment (p = 0.019 and p = 0.03), but in the beraprost sodium therapy group they were relatively stable (p > 0.05).

“After more than 12 months treatment, although the serum creatinine and estimated glomerular filtration rate were significantly worsened in both groups (p < 0.05), the decline of estimated glomerular filtration rate was less in beraprost sodium therapy group than that in control group (− 10.1 vs. − 25.9 ml/min/1.73 m2, p = 0.045).”

To access the entire study, click here.